Recent Updates
Recently added Catalysts

OPK-88003

Phase 2

Type 2 Diabetes Mellitus | Small Molecules | Metabolic |Opko Health Inc.|Trials Updated: Jun 15, 2021

OPK-88003 development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Jan 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment113

FDA Designations

No designations recorded

OPK-88003 clinical trials

OPK-88003 · 1 trial · 1 indication

Phase 2 1
NCT03406377Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes SubjectsType 2 Diabetes Mellitus
COMPLETED113 Analytics
PHASE2COMPLETED
Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
Type 2 Diabetes MellitusUnlock trial analytics

Study Endpoints

Primary Endpoints

Change in HbA1c in Subjects With Type 2 DM
From baseline to 30 weeks

To evaluate the effect of dose escalation of QW SC OPK-88003 vs placebo injections on HbA1c absolute change from baseline to after 30 weeks treatment in subjects with T2DM inadequately controlled with diet and exercise alone, or treated with a stable dose of metformin.

Secondary Endpoints

Mean Percent (%) Body Weight Change
From baseline to 30 weeks
Percent (%) of Subjects With 5% or Greater Body Weight Loss.
30 weeks.
Change From Baseline of Fasting Plasma Glucose (FPG).
30 weeks.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
PlaceboPLACEBO_COMPARATORWater for injection, Sorbitol, L-Methionine, Sodium Acetate Trihydrate
OPK-88003EXPERIMENTAL70 mg/vial (extractable volume 1 mL) (20mg for 4 weeks, 40 mg for 4 weeks and 70 mg for 22 weeks)

Interventions

NameTypeDescription
OPK-88003DRUGOPK-88003 subcutaneous injection
PlaceboDRUGPlacebo subcutaneous injection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * Men or women aged 18 to 80 years with T2DM treated with diet and exercise alone or on a stable dose of metformin (≥ 1000 mg/day), * BMI ≥27 and ≤45 kg/m2 * HbA1c ≥7.0% and ≤10.5% at screening Exclusion Criteria: * Type 1 diabetes mellitus * Previous treatment with incretin m...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about OPK-88003

What is OPK-88003 used for in type 2 diabetes?

OPK-88003 is an investigational small-molecule drug being studied for the treatment of type 2 diabetes mellitus. It was evaluated in a Phase 2 dose-escalation trial in adults with type 2 diabetes. It is not described as an approved therapy and remains in clinical development.

Who is developing OPK-88003?

OPK-88003 is being developed by Opko Health Inc., which trades under the ticker OPK. The company sponsored the Phase 2 clinical program evaluating the small molecule in type 2 diabetes mellitus.

What phase is OPK-88003 in?

OPK-88003 is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed. The drug is investigational and is not described as FDA approved for type 2 diabetes or any other indication.

What clinical trial was conducted for OPK-88003?

OPK-88003 was studied in trial NCT03406377, titled Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects. The Phase 2 trial was completed, enrolled 113 participants, and was conducted in the United States. It was randomized, double-blind, and placebo-controlled, enrolling adults 18 years and older of all sexes.

What kind of drug is OPK-88003?

OPK-88003 is a small-molecule drug in the metabolic therapeutic area. It was developed as an investigational oral agent for type 2 diabetes mellitus and advanced into a completed Phase 2 dose-escalation study in adults with the condition.